Customization: | Available |
---|---|
Powder: | Yes |
Customized: | Non-Customized |
Suppliers with verified business licenses
Audited by an independent third-party inspection agency
Vonorazan Fumarate is a reversible proton pump inhibitor, possessing a powerful and sustained inhibitory effect on gastric acid secretion. Compared with common gastric acid inhibitors such as omeprazole, lansoprazole, etc., this product can be used in only common preparations, with rapid onset and prolonged duration of action.
Compared with traditional irreversible proton pump inhibitors (e.g., omeprazole, esomeprazole, etc.), reversible proton pump inhibitors have the following advantages:
(1) rapid onset of action, and maximum acid suppression will be achieved on the 1st day of administration
(2) oral administration, which is unaffected by the destruction of gastric acid, and does not need to be made into an enteric administration form.
Items | Specifications |
---|---|
Name | Vonoprazan Fumarate |
CAS No. | 1260141-27-2 |
Identification | IR spectrum of sample should be consistent with spectrum of standard |
Residue on ignition | ≤0.1% |
PH | 3.0~4.0 |
Water content | ≤0.5% |
Appearance | White crystalline powder |
Heavy metals | ≤20ppm |
D90 | 14.7um |
5-(2-Fluorophenyl)-N-methyl-1-(3-pyridinylsulfonyl)-1H-pyrrole-3-methanamine (2E)-2-butenedioate (1:1)
1H-Pyrrole-3-methanamine,5-(2-fluorophenyl)-N-methyl-1-(3-pyridinylsulfonyl)-,(2E)-2-butenedioate (1:1);5-(2-Fluorophenyl)-N-methyl-1-(3-pyridinylsulfonyl)-1H-pyrrole-3-methanamine (2E)-2-butenedioate (1:1);TAK 438 monofumarate;TAK 438;Vocinti;Takecab;Vonoprazan fumarate;1260141-27-2
1260141-27-2
C17H16FN3O2S.C4H4O4
InChIKey=ROGSHYHKHPCCJW-WLHGVMLRSA-N
461.4634032